A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Prior treatment

• Underwent surgical treatment, radical radiotherapy, immunotherapy, etc., within 4 weeks before the first dose or within 5 half-lives;
• Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;
• History of severe cardiovascular or cerebrovascular diseases within the past 6 months before screening;
• Concurrent pulmonary disease leading to severe impairment of lung function;
• Required systemic corticosteroid or immunosuppressive therapy within 2 weeks before the study administration;
• Systemic severe infection within 4 weeks before screening;

Other illness

• Diagnosed with other primary malignancies within 5 years before the first dose;
• Poorly controlled hypertension;
• History of non-infectious ILD requiring steroid treatment, or currently suffering from ILD/interstitial pneumonia, etc.;
• Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-M07D1, pembrolizumab, or any excipient components;
• New deep vein thrombosis within 14 days, excluding patients with venous filters implanted;
• Active autoimmune diseases and inflammatory diseases;
• Human immunodeficiency virus antibody positivity, active hepatitis B virus infection, or hepatitis C virus infection;
• History of allogeneic stem cell, bone marrow, or organ transplantation;
• Presence of severe neurological or psychiatric disorders;

Lab values

• QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
• Presence of other severe physical or laboratory abnormalities, poor compliance, etc., which may increase the risk of participation in the study, interfere with study results, or patients deemed unsuitable for participation in the study by the investigator.

Other

• Pathology indicates non-small cell carcinoma containing small cell carcinoma components and sarcomatoid carcinoma;
• Patients with central nervous system metastases, carcinomatous meningitis, and/or spinal cord compression;
• Patients with massive serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;

• Voluntarily sign the informed consent form and comply with the protocol requirements;
• No gender restrictions;
• Age at the time of signing the informed consent form ≥18 years and ≤75 years;
• Expected survival time ≥3 months;
• Patients with locally advanced or metastatic non-squamous non-small cell lung cancer;
• Confirmed known HER2 overexpression;
• Agree to provide archived tumor tissue specimens from primary or metastatic lesions within the past 2 years;
• Must have at least one measurable lesion meeting the RECIST v1.1 criteria;
• ECOG performance status score of 0 or 1;
• Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
• No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
• Organ function levels must meet the requirements;
• For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, serum pregnancy must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should take adequate and highly effective contraception throughout the treatment cycle and for 7 months after the end of treatment.